## (12) United States Patent

#### Yaworski et al.

## (10) **Patent No.:**

## US 8,058,069 B2 Nov. 15, 2011

(45) <b>Date of Patent:</b>	
-----------------------------	--

(54)	LIPID FORMULATIONS FOR NUCLEIC ACID
	DELIVERY

(75) Inventors: Edward Yaworski, Maple Ridge (CA);

Kieu Lam, Surrey (CA); Lloyd Jeffs, Delta (CA); Lorne Palmer, Vancouver (CA); Ian MacLachlan, Mission (CA)

(73) Assignee: **Protiva Biotherapeutics, Inc.**, Burnaby,

B.C. (CA)

Subject to any disclaimer, the term of this (\*) Notice:

patent is extended or adjusted under 35

U.S.C. 154(b) by 0 days.

(21) Appl. No.: 12/424,367

Filed: Apr. 15, 2009 (22)

(65)**Prior Publication Data** 

> US 2010/0130588 A1 May 27, 2010

#### Related U.S. Application Data

(60) Provisional application No. 61/045,228, filed on Apr. 15, 2008.

(51) Int. Cl.

C07H 21/04 (2006.01)C12N 15/88 (2006.01)

(52) **U.S. Cl.** ...... 435/458; 536/24.5

(58) **Field of Classification Search** ....................... 536/24.5;

See application file for complete search history.

#### (56)References Cited

#### U.S. PATENT DOCUMENTS

4,394,448	A	7/1983	Szoka, Jr. et al.
4,438,052	A	3/1984	Weder et al.
4,515,736	A	5/1985	Deamer
4,598,051	A	7/1986	Papahadjopoulos et al.
4,897,355	A	1/1990	Eppstein et al.
5,013,556	A	5/1991	Woodle et al.
5,171,678	A	12/1992	Behr et al.
5,208,036	A	5/1993	Eppstein et al.
5,225,212	$\mathbf{A}$	7/1993	Martin et al.
5,264,618	A	11/1993	Felgner et al.
5,279,833	A	1/1994	Rose
5,283,185	A	2/1994	Epand et al.
5,320,906	A	6/1994	Eley et al.
5,545,412	A	8/1996	Eppstein et al.
5,578,475	A	11/1996	Jessee et al.
5,641,662	A	6/1997	Debs et al.
5,656,743	A	8/1997	Busch et al.
5,703,055		12/1997	Felgner et al.
5,705,385	A	1/1998	Bally et al.
5,820,873	A	10/1998	Choi et al.
5,976,567	A	11/1999	Wheeler et al.
5,981,501	A	11/1999	Wheeler et al.
6,534,484	B1	3/2003	Wheeler et al.
6,586,410	B1	7/2003	Wheeler et al.
6,649,780	B1	11/2003	Eibl et al.
6,815,432	B2	11/2004	Wheeler et al.
6,858,224	B2	2/2005	Wheeler et al.
7,422,902	B1	9/2008	Wheeler et al.
7,799,565	B2 *	9/2010	MacLachlan et al 435/458

2001/0048940 A	A1	12/2001	Tousignant et al.
2003/0077829 A	A1	4/2003	MacLachlan
2003/0143732 A	A1	7/2003	Fosnaugh et al.
2004/0063654 A	A1	4/2004	Davis et al.
2004/0142892 A	A1	7/2004	Finn et al.
2004/0253723 A	A1	12/2004	Tachas et al.
2004/0259247 A	A1	12/2004	Tuschl et al.
2005/0064595 A	A1	3/2005	MacLachlan et al.
2005/0118253 A	A1	6/2005	MacLachlan et al.
2006/0008910 A	A1	1/2006	MacLachlan et al.
2007/0042031 A	A1	2/2007	MacLachlan et al.
2009/0291131 /	A1*	11/2009	Maclachlan et al. 424/450

#### FOREIGN PATENT DOCUMENTS

WO	WO 91/16024 A1	10/1991
WO	WO 93/05162 A1	3/1993
WO	WO 93/12240 A1	6/1993
WO	WO 93/12756 A2	7/1993
WO	WO 93/24640 A2	12/1993
WO	WO 93/25673 A1	12/1993
WO	WO 95/02698 A1	1/1995
WO	WO 95/18863 A1	7/1995
WO	WO 95/35301 A1	12/1995
WO	WO 96/02655 A1	2/1996
WO	WO 96/10390 A1	4/1996
WO	WO 96/40964 A2	12/1996
WO	WO 96/41873 A1	12/1996
WO	WO 01/05374 A1	1/2001
WO	WO 02/034236 A2	5/2002
WO	WO 02/087541 A1	11/2002
WO	WO 03/097805 A2	11/2003
WO	WO 2004/065546 A2	8/2004
WO	WO 2004/110499 A1	12/2004
	(Con	tinued)

## OTHER PUBLICATIONS

Arpicco, S., et al., "Preparation and Characterization of Novel Cationic Lipids Developed for Gene Transfection," Proceed. Int'l Symp. Control. Rel. Bioact. Mater. (Controlled Release Society, Inc.), 1999, vol. 26, pp. 759-760.

Arpicco, S., et al., "Synthesis, characterization and transfection activity of new saturated and unsaturated cationic lipids," IL Farmaco, 2004, vol. 59, pp. 869-878.

Ballas, N., et al., "Liposomes bearing a quaternary ammonium detergent as an efficient vehicle for functional transfer of TMV-RNA into plant protoplasts," Biochimica et Biophysica Acta, 1988, vol. 939, pp. 8-18.

(Continued)

Primary Examiner — Brian Whiteman

(74) Attorney, Agent, or Firm — Kilpatrick Townsend & Stockton LLP

#### (57)**ABSTRACT**

The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.



#### FOREIGN PATENT DOCUMENTS

WO	WO 2005/007196 A2	1/2005
WO	WO 2005/026372 A1	3/2005
WO	WO 2005/120152 A2	12/2005
WO	WO 2009/086558 A1	7/2009
WO	WO 2009/111658 A2	9/2009
WO	WO 2010/042877 A1	4/2010
WO	WO 2010/048228 A2	4/2010
WO	WO 2010/088537 A2	8/2010
WO	WO 2010/105209 A1	9/2010

#### OTHER PUBLICATIONS

Barinaga, M., "Step Taken Toward Improved Vectors for Gene Transfer," Science, 1994, vol. 266, p. 1326.

Bass, Nature, 2001, 411: 428-9.

Beale, G., et al., "Gene Silencing Nucleic Acids Designed by Scanning Arrays: Anti-EGFR Activity of siRNA, Ribozyme and DNA Enzymes Targeting a Single Hybridization-accessible Region using the Same Delivery System," Journal of Drug Targeting, 2003, vol. 11, No. 7, pp. 449-456.

Behr, J.-P., "Synthetic Gene-Transfer Vectors," Acc. Chem. Res., 1993, vol. 26, pp. 274-278.

Brigham, K., et al., "Rapid Communication: In vivo Transfection of Murine Lungs with a Functioning Prokaryotic Gene Using a Liposome Vehicle," The American Journal of the Medical Sciences, vol. 298, No. 4, pp. 278-281, 1989.

Brummelkamp, et al., "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells," Science, 2002, V. 296. pp. 550-553.

Cevc, G., "How Membrane Chain-Melting Phase-Transition Temperature is Affected by the Lipid Chain Asymmetry and Degree of Unsaturation: An Effective Chain-Length Model," Biochemistry, 1991, vol. 30, pp. 7186-7193.

Cortesi, R., et al., "Effect of cationic liposome composition on in vitro cytotoxicity and protective effect on carried DNA," International Journal of Pharmaceutics, 1996, vol. 139, pp. 69-78.

Crystal, R., "Transfer of Genes to Humans: Early Lessons and Obstacles to Success," Science, 1995, vol. 270, pp. 404-410.

Culver K., "The First Human Gene Therapy Experiment," Gene Therapy: A Handbook for Physicians, 1994, pp. 33-40.

Duzgunes, N., "Membrane Fusion," Subcellular Biochemistry, 1985, vol. 11, pp. 195-286.

Dwarki, V.J., et al., "Cationic Liposome-Mediated RNA Transfection," Methods in Enzymology, 1993, vol. 217, pp. 644-654.

Enoch, H., et al., "Formation and properties of 1000-Å-diameter, single-bilayer phospholipid vesicles," Proc. Natl. Acad. Sci. USA, 1979, vol. 76, No. 1, pp. 145-149.

Felgner, J., et al., "Cationic Lipid-Mediated Transfection in Mammalian Cells: 'Lipofection," J. Tiss. Cult. Meth., 1993, vol. 15, pp. 63-68.

Felgner, J., et al., "Enhanced Gene Delivery and Mechanism Studies with a Novel Series of Cationic Lipid Formulations," The Journal of Biological Chemistry, 1994, vol. 269, No. 4, pp. 2550-2561.

Felgner, P., et al., "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure," Proc. Natl. Acad. Sci. USA, 1987, vol. 84, pp. 7413-7417.

Felgner, P.L., et al., "Cationic Liposome Mediated Transfection," Proc. West. Pharmacol. Soc., 1989, vol. 32, pp. 115-121.

Gao, X., et al., "A Novel Cationic Liposome Reagent for Efficient Transfection of Mammalian Cells," Biochem. Biophys. Res. Comm., 1991, vol. 179, No. 1, pp. 280-285.

Gershon, H., et al., "Mode of Formation and Structural Feature of DNA-Cationic Liposome Complexes Used for Transfection," Biochemistry, 1993, vol. 32, pp. 7143-7151.

Guy-Caffey, J., et al., "Novel Polyaminolipids Enhance the Cellular Uptake of Oligonucleotides," The Journal of Biological Chemistry, 1995, vol. 270, No. 52, pp. 31391-31396.

Hawley-Nelson, P., et al., "LipofectAmine™ Reagent: A New, Higher Efficiency Polycationic Liposome Transfection Reagent," Focus, 1993, vol. 15, No. 3, pp. 73-80.

Hyde, S., et al., "Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy," Nature, 1993, vol. 362, pp. 250-255

Jiang, L., et al., "Comparison of protein precipitation methods for sample preparation prior to proteomic analysis," Journal of Chromatography A, 2004, vol. 1023, pp. 317-320.

tography A, 2004, vol. 1023, pp. 317-320.

Juliano, R., et al., "The Effect of Particle Size and Charge on the Clearance Rates of Liposomes and Liposome Encapsulated Drugs," Biochem. Biophys. Res. Commun., 1975, vol. 63, No. 3, pp. 651-658. Keough, K., "Influence of chain unsaturation and chain position on thermotropism and intermolecular interactions in membranes," Biochem. Soc. Transactions, 1990, vol. 18, No. 5, pp. 835-837.

Legendre, J.-Y. et al., "Delivery of Plasmid DNA into Mammalian Cell Lines Using pH- Sensitive Liposomes: Comparison with Cationic Liposomes," Pharm. Res., 1992, vol. 9, No. 10, pp. 1235-1242.

Leventis, R., et al., "Interactions of mammalian cells with lipid dispersions containing novel metabolizable cationic amphiphiles," Biochem. Biophys. Acta, 1990, vol. 1023, pp. 124-132.

Liu, et al., "Cationic Liposome-mediated Intravenous Gene Delivery", J. Biol. Chem., 1995, V. 270, pp. 24864-24870.

Marshall, E., "Gene Therapy's Growing Pains," Science, 1995, vol. 269, pp. 1050-1055.

Orkin, S., et al., NIH Report, Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, 1005

Paul, C., et al., "Effective expression of small interfering RNA in human cells," Nature Biotech., 2002, vol. 20, pp. 505-508.

Puyal, C., et al., "A new cationic liposome encapsulating genetic material: A potential delivery system for polynucleotides," Eur. J. Biochem., 1995, vol. 228, pp. 697-703.

Sorensen, et al., "Gene Silencing by Systemic Delivery of Synthetic siRNAs in Adult Mice", J. Biol. Chem., 2003, V. 327, pp. 761-766. Spagnou, S., et al., "Lipidic Carriers of siRNA: Differences in the Formulation, Cellular Uptake, and Delivery with Plasmid DNA," Biochemistry, 2004, vol. 43, pp. 13348-13356.

Stamatatos, L., et al., "Interactions of Cationic Lipid Vesicles with Negatively Charged Phospholipid Vesicles and Biological Membranes," Biochemistry, 1988, vol. 27, pp. 3917-3925.

Szoka, F., et al., "Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes)," Ann. Rev. Biophys. Bioeng., 1980, vol. 9, pp. 467-508.

Szoka, F., et al., "Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation," Proc. Natl. Acad. Sci. USA, 1978, vol. 75, No. 9, pp. 4194-4198

Templeton, "Cationic Liposome-mediated Gene Delivery In vivo", Bioscience Reports, 2002, vol. 22, No. 2, pp. 283-295.

Van Der Woude, I., et al., "Parameters influencing the introduction of plasmid DNA into cells by the use of synthetic amphiphiles as a carrier system," Biochimica et Biophysica Acta, 1995, vol. 1240, pp. 34-40.

Wheeler, et al., "Stabilized Plasmid-lipid Particles: Constructions and Characterization," Gene Therapy, V. 6, pp. 271-281, 1999.

Wilson, R., et al., "Counterion-Induced Condensation of Deoxyribonucleic Acid," A Light-Scattering Study, Biochemistry, 1979, vol. 18, No. 11, pp. 2192-2196.

Woodle, M.C., et al., "Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes," Biochimica et Biophysica Acta, 1992, vol. 1105, pp. 193-200.

Zhu, N., et al., "Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice," Science, 1993, vol. 261, pp. 209-211. Elbashir, et al.; Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells; Nature; May 2001; pp. 494-498; vol. 411.

\* cited by examiner






FIG. 1A







FIG. 1B



US 8,058,069 B2






FIG. 2



# DOCKET

## Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

